Who owns Anixa Biosciences Inc (ANIX)? Elite investor 13F holders
2 tracked elite investors reported holding Anixa Biosciences Inc as of 2026-06-30, including Renaissance Technologies LLC, Ancora Advisors / Ancora Holdings. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | ANIXA BIOSCIENCES INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 166244.00 USD | 59373.000000 | Shares | reduce | Original filing |
| Ancora Advisors / Ancora Holdings | ANIXA BIOSCIENCES INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 3570.00 USD | 1275.000000 | Shares | hold | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.